In hepatocellular carcinoma cells (HepG2), EA treatment resulted in a notable decrease in both gene and protein expression among several members of the MCM family (MCM2-7) and CDKs (CDK2 and CDK4), concomitantly with upregulated p21 and decreased phosphorylation of pRB [77]. This evidence concerns the gene CDKN1A and hepatocellular carcinoma.